Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | ALB | P02768 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12859393 | 0.84 | ADORA2A (0.40) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL1123893 | 0.83 | ALB (0.46) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL1123696 | 0.75 | KDM4E (0.47) | KDM4ESTAT3HIF1AALDH1A1KMT2A | |
| SCHEMBL2222961 | 0.70 | ADORA2A (0.47) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL10735323 | 0.69 | KDM4E (0.44) | GABRG2GABRB3GABRA2KDM4EALDH1A1 | |
| SCHEMBL28055652 | 0.69 | EGLN1 (0.44) | KDM4ESTAT3HIF1AKMT2ANPSR1 | |
| SCHEMBL24174035 | 0.69 | SSTR4 (0.43) | ADORA2AKDM4ESTAT3HIF1AALDH1A1 | |
| SCHEMBL22492423 | 0.69 | PSMD14 (0.68) | ADORA2AKDM4EKMT2ANPSR1RAB9A | |
| SCHEMBL20545378 | 0.69 | AHR (0.46) | ADORA2AKDM4ESTAT3HIF1AALDH1A1 | |
| SCHEMBL6080236 | 0.69 | AURKA (0.41) | ADORA2AALDH1A1ALBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309552-B2 | Immunomodulating heterocyclic compounds | MEDIGENE AG (DE) | 2012-11-13 | — | — | US | disclosed |
| US-8309552-B2 | Immunomodulating heterocyclic compounds | MEDIGENE AG (DE) | 2012-11-13 | — | — | US | disclosed |
| US-8309552-B2 | Immunomodulating heterocyclic compounds | MEDIGENE AG (DE) | 2012-11-13 | — | — | US | disclosed |
| EP-2284172-A1 | Immunomodulating heterocyclic compounds | MediGene Ltd. (GB) | 2011-02-16 | — | — | EP | disclosed |
| EP-2284172-A1 | Immunomodulating heterocyclic compounds | MediGene Ltd. (GB) | 2011-02-16 | — | — | EP | disclosed |
| EP-1603917-B1 | IMMUNOMODULATING HETEROCYCLIC COMPOUNDS | MEDIGENE LTD (GB) | 2010-11-24 | — | — | EP | disclosed |
| EP-1603917-B1 | IMMUNOMODULATING HETEROCYCLIC COMPOUNDS | MEDIGENE LTD (GB) | 2010-11-24 | — | — | EP | disclosed |
| US-20090312334-A1 | Immunomodulating Heterocyclic Compounds | MEDIGENE LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
| US-20090312334-A1 | Immunomodulating Heterocyclic Compounds | MEDIGENE LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
| US-20090312334-A1 | Immunomodulating Heterocyclic Compounds | MEDIGENE LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
| US-20080045527-A1 | Immunomodulating Heterocyclic Compounds | MEDIGENE LIMITED (GB) | 2008-02-21 | — | — | US | disclosed |
| US-20080045527-A1 | Immunomodulating Heterocyclic Compounds | MEDIGENE LIMITED (GB) | 2008-02-21 | — | — | US | disclosed |
| US-7276505-B2 | Immunomodulating heterocyclic compounds | MEDIGENE LIMITED (GB) | 2007-10-02 | — | — | US | disclosed |
| US-7276505-B2 | Immunomodulating heterocyclic compounds | MEDIGENE LIMITED (GB) | 2007-10-02 | — | — | US | disclosed |
| US-7276505-B2 | Immunomodulating heterocyclic compounds | MEDIGENE LIMITED (GB) | 2007-10-02 | — | — | US | disclosed |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | AVIDEX LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | AVIDEX LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | AVIDEX LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| EP-1603917-A1 | IMMUNOMODULATING HETEROCYCLIC COMPOUNDS | Avidex Limited (GB) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004081011-A1 | IMMUNOMODULATING HETEROCYCLIC COMPOUNDS | AVIDEX LIMITED (GB) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312334-A1 | Immunomodulating Heterocyclic Compounds | CD40, CD40LG, NGFR | GABRA1 1044/4885GABRG2 1106/4885GABRB3 880/4885 |
| US-20080045527-A1 | Immunomodulating Heterocyclic Compounds | CD40, CD40LG, NGFR | GABRA1 1044/4885GABRG2 1106/4885GABRB3 880/4885 |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | CD40, CD40LG, NGFR | GABRA1 991/4885GABRG2 1103/4885GABRB3 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.